Cannamedical® Pharma GmbH

cannamedical.com

Cannamedical® Pharma GmbH has a pharmaceutical wholesale licence in accordance with 52a of the Medicines Act (AMG) and a permit to handle narcotics in accordance with § 3 of the Act on Narcotics (BtMG). As the only independent German cannabis wholesaler we cooperate with several selected international producers. Our independence guarantees a qualitatively and quantitatively unique range of medical cannabis on the German market. In addition to our independence we were also one of the first companies that received the license to import cannabis to Europe. As the laws in Germany only changed in March 2017, making medical cannabis legal, we were one of the very first to deal with the authorities and have since obtained 7 different licenses, allowing us to import from any GMP production in the world. Thus we are one of the pioneers in the European cannabis industry and have become specialists in GMP processing and authority auditing. With our strong team, we are committed to act responsibly and ethically at all times. We fulfill our social responsibility and tasks with passion and dedication. Our clear focus lies on ensuring the adequate supply of medical care for patients, providing information within a professional framework and satisfying our customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

CATALENT ANNOUNCES NEW OPERATING STRUCTURE

Catalent, Inc | July 06, 2022

news image

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue. According to Alessandro Mas...

Read More

Pharma Tech

MEDABLE AND CVS HEALTH ANNOUNCE COLLABORATION TO EXPAND CLINICAL TRIAL ACCESS

Medable Inc. and CVS Health | February 08, 2022

news image

Medable Inc. and CVS Health announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic™ locations via Medable’s clinical trials software platform. CVS Health Clinical Trial Services™ will manage the relationship. The collaboration combines Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to effectively deliver clinical trials in a way that improves pa...

Read More

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

news image

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More

Business Insights

EYEPOINT PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

EyePoint Pharmaceuticals, Inc. | April 19, 2022

news image

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 56,500 shares of EyePoint Ph...

Read More
news image

Business Insights

CATALENT ANNOUNCES NEW OPERATING STRUCTURE

Catalent, Inc | July 06, 2022

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue. According to Alessandro Mas...

Read More
news image

Pharma Tech

MEDABLE AND CVS HEALTH ANNOUNCE COLLABORATION TO EXPAND CLINICAL TRIAL ACCESS

Medable Inc. and CVS Health | February 08, 2022

Medable Inc. and CVS Health announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic™ locations via Medable’s clinical trials software platform. CVS Health Clinical Trial Services™ will manage the relationship. The collaboration combines Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to effectively deliver clinical trials in a way that improves pa...

Read More
news image

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More
news image

Business Insights

EYEPOINT PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

EyePoint Pharmaceuticals, Inc. | April 19, 2022

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 56,500 shares of EyePoint Ph...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us